SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
for Glioma
Sites in Boston +41 more locations
Sponsor: Nuvation Bio Inc.
Sex: All·Age: 18+
Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022
Oncology Clinical Trials in Boston, MA
As of July 2026, 607 paid clinical trials are recruiting for Oncology in Boston, Massachusetts. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
611 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
for Melanoma
Sites in Boston, Newton +29 more locations
Sponsor: Pfizer
Sex: All·Age: 16+
Code: NCT05355701·Phase 1·Recruiting·Listed May 2022
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for Ovarian Cancer
Drug: Bevacizumab
Sites in Boston +31 more locations
Sponsor: Daiichi Sankyo
Sex: Female·Age: 18+
Code: NCT06819007·Phase 3·Recruiting·Listed Feb 2025
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
for Breast Cancer
Sites in Boston +23 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
for Triple Negative Breast Cancer
Sites in Boston +25 more locations
Sponsor: Day One Biopharmaceuticals, Inc.
Sex: All·Age: 18+
Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
for Advanced Solid Tumor
Sites in Boston +30 more locations
Sponsor: PMV Pharmaceuticals, Inc
Sex: All·Age: 12+
Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
for Metastatic Breast Cancer
Sites in Boston +30 more locations
Sponsor: LeonaBio
Sex: All·Age: 18+
Code: NCT05696626·Phase 3·Recruiting·Listed Jan 2023
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
for Acute Leukemia
Sites in Boston +22 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 2+
Code: NCT04811560·Phase 1, Phase 2·Recruiting·Listed Mar 2021
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
for Head and Neck Squamous Cell Carcinoma
Sites in Boston +28 more locations
Sponsor: Tempus AI
Sex: All·Age: 18+
Code: NCT06163534·Recruiting·Listed Dec 2023
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
for B-cell Malignancy
Sites in Boston +27 more locations
Sponsor: BeOne Medicines
Sex: All·Age: 18+
Code: NCT05006716·Phase 1, Phase 2·Recruiting·Listed Aug 2021
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
for Non-small Cell Lung Cancer
Sites in Boston +22 more locations
Sponsor: Genentech, Inc.
Sex: All·Age: 18+
Code: NCT04302025·Phase 2·Recruiting·Listed Mar 2020
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
for Prostate Cancer
Sites in Boston +24 more locations
Sponsor: Novartis Pharmaceuticals
Sex: Male·Age: 18 - 100
Code: NCT06855277·Phase 3·Recruiting·Listed Mar 2025
A Phase 1/1b Study of IAM1363 in HER2 Cancers
for HER2 Mutation-Related Tumors
Sites in Boston +28 more locations
Sponsor: Iambic Therapeutics, Inc
Sex: All·Age: 18+
Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
for Prostate Cancer
Sites in Boston +26 more locations
Sponsor: Novartis Pharmaceuticals
Sex: Male·Age: 18 - 100
Code: NCT06780670·Phase 2, Phase 3·Recruiting·Listed Jan 2025
FOG-001 in Locally Advanced or Metastatic Solid Tumors
for Cancer
Sites in Boston +29 more locations
Sponsor: Parabilis Medicines, Inc.
Sex: All·Age: 18+
Code: NCT05919264·Phase 1, Phase 2·Recruiting·Listed Jun 2023
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
for Breast Cancer
Sites in Boston +48 more locations
Sponsor: Greenwich LifeSciences, Inc.
Sex: All·Age: 18 - 100
Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
for Follicular Lymphoma
Drug: Golcadomide
Sites in Boston +30 more locations
Sponsor: Celgene
Sex: All·Age: 18+
Code: NCT06911502·Phase 3·Recruiting·Listed Apr 2025
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
for Multiple Myeloma
Drug: Elranatamab
Sites in Boston, Newton +32 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT06215118·Phase 1·Recruiting·Listed Jan 2024
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
for Multiple Myeloma
Sites in Boston +37 more locations
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All·Age: 18+
Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
for Small Cell Lung Cancer
Sites in Boston +29 more locations
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06203210·Phase 3·Recruiting·Listed Jan 2024
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
for Glioblastoma
Sites in Boston +31 more locations
Sponsor: NovoCure GmbH
Sex: All·Age: 18+
Code: NCT06556563·Phase 3·Recruiting·Listed Aug 2024
Pan Tumor Rollover Study
for Cancer
Sites in Boston +7 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT03899155·Phase 2·Recruiting·Listed Apr 2019
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
for Myelofibrosis
Sites in Boston +29 more locations
Sponsor: Sumitomo Pharma America, Inc.
Sex: All·Age: 18+
Code: NCT04176198·Phase 1, Phase 2·Recruiting·Listed Nov 2019
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
for AML
Sites in Boston +35 more locations
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT06001788·Phase 1·Recruiting·Listed Aug 2023
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
for Leukemia, Myeloid, Acute
Sites in Boston +29 more locations
Sponsor: Sumitomo Pharma America, Inc.
Sex: All·Age: 12+
Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
for Myelodysplastic Syndrome
Sites in Boston +41 more locations
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT04227847·Phase 1·Recruiting·Listed Jan 2020
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
for Neoplasms
Sites in Boston +24 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 1 - 39
Code: NCT05999994·Phase 2·Recruiting·Listed Aug 2023
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
for Colorectal Cancer
Sites in Boston +31 more locations
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06445062·Phase 1, Phase 2·Recruiting·Listed Jun 2024
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
for Acute Myeloid Leukemia
Drug: Venetoclax
Sites in Boston, Worcester +42 more locations
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
for Brain Tumor, Recurrent
Sites in Boston +51 more locations
Sponsor: GT Medical Technologies, Inc.
Sex: All·Age: All ages
Code: NCT04427384·Recruiting·Listed Jun 2020
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
for Hormone Receptor Positive HER-2 Negative Breast Cancer
Sites in Boston +33 more locations
Sponsor: Puma Biotechnology, Inc.
Sex: All·Age: 18+
Code: NCT06369285·Phase 2·Recruiting·Listed Apr 2024
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
for Non-Small Cell Lung Cancer
Drug: Ivonescimab
Sites in Boston, Milton +87 more locations
Sponsor: Summit Therapeutics
Sex: All·Age: 18+
Code: NCT06767514·Phase 3·Recruiting·Listed Jan 2025
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
for Advanced Breast Cancer
Sites in Boston +34 more locations
Sponsor: Stemline Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06638307·Phase 1·Recruiting·Listed Oct 2024
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
for Cancer Harboring BRAF Alterations
Sites in Boston +28 more locations
Sponsor: Fore Biotherapeutics
Sex: All·Age: 10+
Code: NCT05503797·Phase 2·Recruiting·Listed Aug 2022
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
for Epithelial Ovarian Cancer
Sites in Boston +25 more locations
Sponsor: TORL Biotherapeutics, LLC
Sex: Female·Age: 18+
Code: NCT06690775·Phase 2·Recruiting·Listed Nov 2024
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
for Myelofibrosis
Drug: Ruxolitinib
Sites in Boston +57 more locations
Sponsor: Kartos Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
for Breast Cancer
Drug: Palazestrant
Sites in Boston +39 more locations
Sponsor: Olema Pharmaceuticals, Inc.
Sex: All·Age: 18+
Code: NCT06016738·Phase 3·Recruiting·Listed Aug 2023
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
for Pancreatic Cancer
Drug: daraxonrasib
Sites in Boston +10 more locations
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT07491445·Phase 3·Recruiting·Listed Mar 2026
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
for Solid Tumors
Drug: Adagrasib
Sites in Boston +14 more locations
Sponsor: Mirati Therapeutics Inc.
Sex: All·Age: 18+
Code: NCT07415031·Phase 2·Recruiting·Listed Feb 2026
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
for Glioblastoma (GBM)
Sites in Boston +20 more locations
Sponsor: Black Diamond Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026
Conditions in Oncology (Boston, MA)
Solid tumor· 111Breast cancer· 79Non-small cell lung cancer (NSCLC)· 65Prostate cancer· 43Cancer (any)· 41Colorectal cancer· 39Acute myeloid leukemia (AML)· 36Ovarian cancer· 35Non-Hodgkin lymphoma· 33Multiple myeloma· 32Metastatic breast cancer· 31Pancreatic cancer· 31Endometrial cancer· 30Lung cancer· 28Head and neck cancer· 26Esophageal cancer· 23Gastric cancer· 22Myelodysplastic syndromes (MDS)· 21Glioblastoma· 19Chronic lymphocytic leukemia (CLL)· 19Triple-negative breast cancer· 18Leukemia (other)· 18Hematologic malignancy· 16Bladder cancer· 14Glioma· 13Metastatic prostate cancer· 12Kidney cancer· 12Melanoma· 12Neuroblastoma· 12Follicular lymphoma· 11Small lymphocytic lymphoma· 11Small cell lung cancer· 10Cervical cancer· 10HER2-negative breast cancer· 9Biliary tract cancer· 9Fallopian tube cancer· 9Brain cancer· 9Myelofibrosis· 9Diffuse large B-cell lymphoma (DLBCL)· 9Skin cancer· 9Sarcoma· 9HER2-positive breast cancer· 8Rectal cancer· 7Liver cancer· 7Myeloproliferative neoplasm· 7Mantle cell lymphoma· 7Thyroid cancer· 7Colon cancer· 6Gastroesophageal junction cancer· 6Hodgkin lymphoma· 6Pediatric cancer· 6Mesothelioma· 6Gastrointestinal cancer· 5Brain metastases· 5Acute lymphoblastic leukemia· 5Marginal zone lymphoma· 5Osteosarcoma· 5Ewing sarcoma· 5Metastatic colorectal cancer· 4Uterine cancer· 3Gynecologic cancer· 3Chronic myelomonocytic leukemia· 3Rhabdomyosarcoma· 3Burkitt lymphoma· 2Soft tissue sarcoma· 1Neuroendocrine tumors· 1